These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 19114684)
1. Morphology and more specific immunohistochemical stains are fundamental prerequisites in detection of unknown primary cancer. Rossi G; Nannini N; Costantini M J Clin Oncol; 2009 Feb; 27(4):649-50; author reply 650-2. PubMed ID: 19114684 [No Abstract] [Full Text] [Related]
3. [The pathological practice for metastatic carcinoma of unknown primary-the current status and future prospect]. Watanabe M Gan To Kagaku Ryoho; 2009 Jun; 36(6):910-4. PubMed ID: 19542710 [TBL] [Abstract][Full Text] [Related]
4. [The CUP syndrome--malignant disease with unknown primary tumor. Part 2: Histology--immunohistology]. Jaspersen D Fortschr Med; 1992 Oct; 110(29):541-2. PubMed ID: 1385284 [No Abstract] [Full Text] [Related]
6. [CUP syndrome: are there advances?]. Moll R Verh Dtsch Ges Pathol; 2005; 89():125-36. PubMed ID: 18035682 [TBL] [Abstract][Full Text] [Related]
7. [The value of immunohistochemistry in routine histologic diagnosis of metastases of unknown primary tumors]. Krüger R; de Leon F; Maihoff J Pathologe; 1992 Apr; 13(2):65-72. PubMed ID: 1603774 [No Abstract] [Full Text] [Related]
8. Differential diagnosis in immunohistochemistry with Bayes theorem. Vollmer RT Am J Clin Pathol; 2009 May; 131(5):723-30. PubMed ID: 19369634 [TBL] [Abstract][Full Text] [Related]
9. Pathological evaluation of neoplasms with unknown primary tumor site. Mackay B; Ordonez NG Semin Oncol; 1993 Jun; 20(3):206-28. PubMed ID: 8503017 [No Abstract] [Full Text] [Related]
10. Treatment for patients with unknown primary cancer and favorable prognostic factors. Hainsworth JD; Fizazi K Semin Oncol; 2009 Feb; 36(1):44-51. PubMed ID: 19179187 [TBL] [Abstract][Full Text] [Related]
11. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. Melotte V; Lentjes MH; van den Bosch SM; Hellebrekers DM; de Hoon JP; Wouters KA; Daenen KL; Partouns-Hendriks IE; Stessels F; Louwagie J; Smits KM; Weijenberg MP; Sanduleanu S; Khalid-de Bakker CA; Oort FA; Meijer GA; Jonkers DM; Herman JG; de Bruïne AP; van Engeland M J Natl Cancer Inst; 2009 Jul; 101(13):916-27. PubMed ID: 19535783 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of Carcinoma of Unknown Primary on Cytologic Specimens. Doxtader EE; Chute DJ Surg Pathol Clin; 2018 Sep; 11(3):545-562. PubMed ID: 30190140 [TBL] [Abstract][Full Text] [Related]
13. Use of biological markers in the diagnosis of cancers of unknown primary tumor. Ruddon RW; Norton SE Semin Oncol; 1993 Jun; 20(3):251-60. PubMed ID: 8503021 [No Abstract] [Full Text] [Related]
14. Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. Greco FA; Pavlidis N Semin Oncol; 2009 Feb; 36(1):65-74. PubMed ID: 19179190 [TBL] [Abstract][Full Text] [Related]
16. Expression of nerve growth factor and tyrosine kinase receptor A and correlation with perineural invasion in pancreatic cancer. Ma J; Jiang Y; Jiang Y; Sun Y; Zhao X J Gastroenterol Hepatol; 2008 Dec; 23(12):1852-9. PubMed ID: 19120874 [TBL] [Abstract][Full Text] [Related]
17. Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma. Jagdis A; Rubin BP; Tubbs RR; Pacheco M; Nielsen TO Am J Surg Pathol; 2009 Dec; 33(12):1743-51. PubMed ID: 19809272 [TBL] [Abstract][Full Text] [Related]